BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla cash
Cash and short-term investments held at the end of each period.
BioAtla's cash was $1.54M at Jun 30, 2026. For fiscal 2025 it was $7.12M, down 85.5% from the year before. The highest annual figure on record is $244.98M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.12M | -85.5% |
| FY2024 | Dec 31, 2024 | $49.05M | -56.0% |
| FY2023 | Dec 31, 2023 | $111.47M | -48.3% |
| FY2022 | Dec 31, 2022 | $215.51M | -12.0% |
| FY2021 | Dec 31, 2021 | $244.98M | +2.7% |
| FY2020 | Dec 31, 2020 | $238.61M | +6341.8% |
| FY2019 | Dec 31, 2019 | $3.70M | -65.9% |
| FY2018 | Dec 31, 2018 | $10.86M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.54M | -91.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.96M | -93.9% |
| Q4 FY2025 | Dec 31, 2025 | $7.12M | -85.5% |
| Q3 FY2025 | Sep 30, 2025 | $8.32M | -85.3% |
| Q2 FY2025 | Jun 30, 2025 | $18.21M | -70.5% |
| Q1 FY2025 | Mar 31, 2025 | $32.36M | -59.9% |
| Q4 FY2024 | Dec 31, 2024 | $49.05M | -56.0% |
| Q3 FY2024 | Sep 30, 2024 | $56.52M | -60.0% |
| Q2 FY2024 | Jun 30, 2024 | $61.66M | -63.4% |
| Q1 FY2024 | Mar 31, 2024 | $80.63M | -58.2% |
| Q4 FY2023 | Dec 31, 2023 | $111.47M | -48.3% |
| Q3 FY2023 | Sep 30, 2023 | $141.28M | -20.7% |
| Q2 FY2023 | Jun 30, 2023 | $168.69M | -16.6% |
| Q1 FY2023 | Mar 31, 2023 | $192.69M | -12.2% |
| Q4 FY2022 | Dec 31, 2022 | $215.51M | -12.0% |
| Q3 FY2022 | Sep 30, 2022 | $178.12M | -34.0% |
| Q2 FY2022 | Jun 30, 2022 | $202.29M | -2.6% |
| Q1 FY2022 | Mar 31, 2022 | $219.43M | -0.8% |
| Q4 FY2021 | Dec 31, 2021 | $244.98M | +2.7% |
| Q3 FY2021 | Sep 30, 2021 | $269.93M | +375.6% |
| Q2 FY2021 | Jun 30, 2021 | $207.61M | +112731.0% |
| Q1 FY2021 | Mar 31, 2021 | $221.20M | +59683.5% |
| Q4 FY2020 | Dec 31, 2020 | $238.61M | +6341.8% |
| Q3 FY2020 | Sep 30, 2020 | $56.76M | +422.5% |
| Q2 FY2020 | Jun 30, 2020 | $184.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $370.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $3.70M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.86M | – |
See a number that looks wrong?